Pulmonary toxicity of systemic lung cancer therapy-Reference-Cited by-同舟云学术

Pulmonary toxicity of systemic lung cancer therapy

Published:2020-07-29 Issue:S2 Volume:25 Page:72-79
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:Respirology

Author:

Long Kathryn¹,Suresh Karthik¹^ORCID

Affiliation:

1. Division of Pulmonary Critical Care Medicine Johns Hopkins University School of Medicine Baltimore MD USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.13915

Reference67 articles.

1. Current status of research and treatment for non-small cell lung cancer in never-smoking females

2. Cancer statistics, 2020

3. The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)

4. National Comprehensive Cancer Network. Version 2.2020: NCCN Clinical Practice Guidelines in Oncology: Non‐Small Cell Lung Cancer.2019. [Accessed 1 Jan 2020.] Available from URL:https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

5. Interstitial lung disease associated with docetaxel in patients with advanced non‐small cell lung cancer;Tamiya A;Anticancer Res.,2012

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report;Current Cancer Drug Targets;2024-07-05

2. Lower Income, Smoking, Cardiopulmonary Comorbidities, and Higher Symptom Burden Influence the Occurrence of Cough in Patients Receiving Chemotherapy;Oncology Nursing Forum;2024-07-01

3. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

4. Drug-induced Lung Disease in the Oncology Patient;Clinics in Chest Medicine;2024-06

5. Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in non-small cell lung cancer;Molecular Medicine;2024-04-26